Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Schey

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Leukemia Research|July 16, 2003
An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatmentS A Schey, J Cavenagh, R Johnson, et al.
Vox Sanguinis|January 1, 1997
Audit of practice in platelet refractorinessK J Phekoo, H Hambley, S A Schey, et al.
Journal of the Royal College of Physicians of London|May 1, 1997
Folate assays: serum or red cell?K Phekoo, Y Williams, S A Schey, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Serum osteocalcin in the management of myelomaA T Williams, M J Shearer, J Oyeyi, et al.
British Journal of Haematology|November 11, 1999
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study GroupG R Morgenstern, A G Prentice, H G Prentice, et al.
British Journal of Haematology|October 20, 2004
A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UKK J Phekoo, S A Schey, M A Richards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2004
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myelomaS A Schey, P Fields, J B Bartlett, et al.
British Journal of Haematology|October 23, 1997
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patientsH G Prentice, I M Hann, R Herbrecht, et al.
Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.
Leukemia|April 17, 2013
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsY-T Tai, Y Landesman, C Acharya, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Leukemia Research|July 16, 2003
An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatmentS A Schey, J Cavenagh, R Johnson, et al.
Vox Sanguinis|January 1, 1997
Audit of practice in platelet refractorinessK J Phekoo, H Hambley, S A Schey, et al.
Journal of the Royal College of Physicians of London|May 1, 1997
Folate assays: serum or red cell?K Phekoo, Y Williams, S A Schey, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Serum osteocalcin in the management of myelomaA T Williams, M J Shearer, J Oyeyi, et al.
British Journal of Haematology|November 11, 1999
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study GroupG R Morgenstern, A G Prentice, H G Prentice, et al.
British Journal of Haematology|October 20, 2004
A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UKK J Phekoo, S A Schey, M A Richards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2004
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myelomaS A Schey, P Fields, J B Bartlett, et al.
British Journal of Haematology|October 23, 1997
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patientsH G Prentice, I M Hann, R Herbrecht, et al.
Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.
Leukemia|April 17, 2013
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsY-T Tai, Y Landesman, C Acharya, et al.
Pageof 2